Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24

Goodwin, Rachel; Ding, Keyue; Seymour, Lesley; Lemaître, Anne-Iris; Arnold, Andrew; Shepherd, Frances A.; Dediu, Mircea; Ciuleanu, Tudor-Eliade; Fenton, David; Zukin, Mauro; Walde, David; Laberge, Francis; Vincent, Mark; Ellis, Peter; Laurie, Scott A.

doi:10.1093/annonc/mdq221

Cited by 41 publications

(24 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of hypertension reported for the different RTKIs shows considerable variation, and especially, high rates of hypertension in over 60% of patients have been reported for the RTKIs cediranib and lenvatinib. 20,21 The reported difference in the incidence of hypertension may be explained by the intensity of blockade of the VEGFR-2 induced by the different VSP inhibitors. Furthermore, blockade of additional tyrosine kinases by the different RTKIs may play a role in the development of hypertension either by contributing to or by antagonizing the rise in BP.…”

Section: Incidence Of Hypertension and Renal Injurymentioning

confidence: 99%

Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition

Meiracker

Danser

2016

Hypertension

View full text Add to dashboard Cite

Section: Incidence Of Hypertension and Renal Injurymentioning

confidence: 99%

Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition

Meiracker

Danser

2016

Hypertension

View full text Add to dashboard Cite

“…In a study using axitinib treatment for Japanese patients with MKC, Tomita et al (11) indicated that baseline proteinuria and soluble VEGFR-2 levels may be predictive factors of axitinib-induced proteinuria, which may also be a predictive factor of a good response to axitinib. With regard to HT, a study of the VEGFR-TKI, cediranib, for non-small cell lung cancer indicated that predictors of VEGFR-TKI-induced HT were as follows: Eastern Cooperative Oncology Group performance status 0; female; normal lactate dehydrogenase levels; and no prior peripheral vascular disease (12). A meta-analysis of sunitinib indicated a significantly higher incidence of sunitinib-induced HT in MKC compared with gastrointestinal stromal tumors (13).…”

Section: Discussionmentioning

confidence: 99%

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients

et al. 2014

View full text Add to dashboard Cite

Hypertension (HT) is the common adverse event associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). The present study was performed to identify the predictive factors of TKI-induced HT and to determine the classes of antihypertensive agents (AHTA) that demonstrate optimal efficacy against this type of HT. The charts of 50 cases of patients that had received VEGFR-TKI treatment were retrospectively examined. The association between patient background and TKI-induced HT, and the effect of administering AHTA were analyzed. High systolic blood pressure at baseline was identified to be a predictive factor for HT. In addition, there was no difference observed between calcium channel blockers (CCBs) and angiotensin receptor II blockers (ARBs) as first-line AHTA for the control of HT. The findings of the present study may aid with predicting the onset of TKI-induced HT, as well as for its management via the primary use of either CCBs or ARBs.

show abstract

“…Existing data indicate a possible predictive role for single nucleotide polymorphisms (SNPs) in the VEGF signaling pathway, as well as treatment-emergent hypertension, but the clinical importance of this remains to be evaluated [48]. However, another VEGF receptor inhibitor, cediranib, showed no predictive association for hypertension in the NCIC Clinical Trials Group study BR24 [49].…”

Section: Angiogenesis Inhibitionmentioning

confidence: 99%

Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)

Mascaux

Ekman

Dooms³

et al. 2012

Curr Respir Care Rep

View full text Add to dashboard Cite

Based on meta-analyses and the results of several trials, adjuvant chemotherapy is currently recommended for stage II and stage III non-small cell lung cancer (NSCLC) patients after complete tumor resection, and may be considered for patients with stage IB NSCLC ≥ 4 cm. As individualized therapy becomes integrated into the care of advanced NSCLC, its role in early stage NSCLC and, in particular, in the adjuvant setting, also will become of greater importance. In the adjuvant setting, prognostic and predictive biomarkers might identify which patients have a worse prognosis and, among them, those who could benefit from customized chemotherapy. In the present review, we summarized the available data and ongoing trials testing the role of individualized adjuvant therapy (chemotherapy, targeted therapy and immunotherapy) in NSCLC.

show abstract

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24

Abstract: In advanced NSCLC, HTN is frequent in patients receiving chemotherapy, with or without cediranib. The development of HTN was favorably prognostic in these patients, but not predictive of a differential outcome with cediranib.

Cited by 41 publications

References 32 publications

Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition

Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients

Individualized therapy in the adjuvant setting for non-small cell lung cancer (NSCLC)

Contact Info

Product

Resources

About